| Identification | Back Directory | [Name]
3-Ethynylimidazo[1,2-b]pyridazine | [CAS]
943320-61-4 | [Synonyms]
Ponatinib Impurity 1
3-Ethynylimidazo[1,2-b]pyridazine
3-Ethynylimidazolo[1,2-b]pyridazine
IMidazo[1,2-b]pyridazine, 3-ethynyl- | [Molecular Formula]
C8H5N3 | [MDL Number]
MFCD17012027 | [MOL File]
943320-61-4.mol | [Molecular Weight]
143.15 |
| Chemical Properties | Back Directory | [density ]
1.15±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [form ]
solid | [pka]
3.71±0.30(Predicted) | [color ]
White to grey | [InChI]
InChI=1S/C8H5N3/c1-2-7-6-9-8-4-3-5-10-11(7)8/h1,3-6H | [InChIKey]
VYOHSFQVMLAURO-UHFFFAOYSA-N | [SMILES]
C12=NC=C(C#C)N1N=CC=C2 |
| Hazard Information | Back Directory | [Uses]
3-Ethynylimidazo[1,2-b]pyridazine is used as an intermediate of Ponatinib, a BCR-ABL tyrosine kinase inhibitor anticancer drug used in the treatment of chronic myeloid leukaemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). |
|
|